Eluting

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System f...

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

Company Enrolls First Patient into SPIRIT PRIME Trial in the United States ABBOTT PARK, Ill., June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) E...

XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration

MENLO PARK, Calif., June 4 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical pro...

Better patient outcomes with drug eluting stents

Patients receiving drug eluting stents (DES) stents coated with medication to prevent narrowing of the artery as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ http://www.cmaj.ca/press/080050.pdf...

Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels

ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treat...

Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan

Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting Stent TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced that it has submitted an application for Seizo Hanbai Shonin (Marketing Authorization L...

Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent

New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting Coronary ...

Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions

- Five hundred patients treated with company's AXXESS(TM) System to date - LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- Devax, Inc., a medical device company focused on developing next generation products for interventional cardiology, today announced that the Company has completed patient enro...

FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-genera...

Aeon Bioscience Continues Development of Drug Eluting Stents

BIRMINGHAM, Ala., Oct. 10 /PRNewswire-USNewswire/ -- Aeon Bioscience, Inc. today announced the recent acquisition of one of its key collaborators, Brookwood Pharmaceuticals, Inc. by SurModics, Inc., a major development in its quest to develop improvements in drug-eluting stent technology for t...

Eluting in Medical Technology

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

WARRENDALE, Pa., May 18 /PRNewswire/ -- MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial ...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are pros...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinic...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

Data Demonstrate Bioabsorbable Stent Is Absorbed Within Two Years, Leaving Behind Blood Vessels that Appear to Move and Function Similar to Untreated Vessels ABBOTT PARK, Ill., March 12 /PRNewswire-FirstCall/ -- A comprehensive analysis published today in The Lancet , one of the world's le...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

ABBOTT PARK, Ill., Jan. 26 /PRNewswire-FirstCall/ -- Data published online today in Circulation from the SPIRIT III U.S. pivotal trial evaluating the XIENCE V(TM) Everolimus Eluting Coronary Stent System demonstrated that Abbott's market-leading XIENCE V outperforms the TAXUS(R) Express2(TM)...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today f...

Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

SPIRIT III Results Demonstrate Superior Reduction in In-Segment Late Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE with XIENCE V Compared to TAXUS ABBOTT PARK, Ill., April 22 /PRNewswire-FirstCall/ -- A study published in today's Journal of the A...

Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V - CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out t...

Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

One-Year Data on First 30 Patients Enrolled in Ongoing Study Presented at TCT WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced continued positive results from ABSORB, the world's first clinical trial evaluating the safety and pe...

More>>

Eluting in Medical Products

CoStar Paclitaxel-eluting Coronary Stent System

Description:...systems COSTAR paclitaxel stent. Radically different from conventional drug eluting stents, the CONOR Medsystems stent is the first non-surface-coated drug eluting stent designed to provide advanced drug delivery capabilities. CONOR Medsys...
Company:Biotronik GmbH & Co.

Selute® Picotip Atrial J

Description:... Steroid eluting pacemaker leads with preformed J...
Company:Guidant Corporation

Selute Picotip

Description:... Steroid eluting pacemaker leads...
Company:Guidant Corporation

Sweet Picotip RX

Description:... Steroid eluting pacemaker leads...
Company:Guidant Corporation

Sweet Picotip® RX

Description:... Steroid eluting pacemaker leads...
Company:Guidant Corporation

Selute Picotip Atrial J

Description:... Selute Picotip Atrial-J steroid eluting passive fixation lead...
Company:Guidant Corporation

Attain OTW Model 4194 Bi-Polar

Features:... Angled distal end designed for steerability and stable fixation in range of veins Steroid eluting designed to minimize threshold peaking Exclusive tip seal designed to minimize blood ingress to the lead body, and designed to facilitate rep...
Company:Medtronic Inc.

Attain™ OTW Left-heart Lead

Features:... Angled distal end designed for steerability and stable fixation in range of veins. Steroid eluting designed to minimize threshold peaking. Exclusive tip seal designed to minimize blood ingress to the lead body, and designed to facilitate reposition...
Company:Medtronic Inc.

Brilliant S+

Features:...r passage and positioning. The special designed flexible connectors and small bifurcation sleeve facilitate wrapping around the pacemaker. The steroid eluting electrode provides lower acute and chronic pacing thresholds allowing low pacing output settings. Tip - center atrial rings: 15.5 cm....
Company:Vitatron B.V.

Impulse

Features:...eases the impedance to deliver energy most efficiently. The high impedance saves energy and extends the pacemaker longevity significantly. The steroid eluting electrode provides low acute and chronic pacing thresholds, allowing low output programming. The small 6F lead body allows easier passage and position...
Company:Vitatron B.V.

Eluting in Medical Dictionary

Stent

...y balloon angioplasty - series ... Coronary heart disease (CHD) (angioplasty and stent placement - heart) ... DESCRIPTION ... Home " Drug eluting Stent Center " Overview ... The concept of the stent grew directly out of interventional cardiologists' ... A stent is a small mesh-wire tub...

Eluting in Biological News

The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent

ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-t...

Supercomputing equipment to advance the frontiers of computational biology

... develop simulations for prototyping medical devices in "virtual patients," with potential applications in targeted drug delivery systems such as drug eluting stents, transdermal patches, and inhalers. To be successful, these simulations must run efficiently and effectively on the latest generation of h...

Eluting in Biological Technology

Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough Treatment for the Most Common Form of Heart Disease ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronar...

Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years

Zero Incidence of Late Stent Thrombosis Reported in CUSTOM I, II, and III Trials WASHINGTON and MENLO PARK, Calif., Oct. 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced positive long-term follow-up data from the CUSTOM I, II and III clin...

Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent

XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease Patients in Real-World Setting ABBOTT PARK, Ill., July 9 /PRNewswire-FirstCall/ -- Abbott today announced the start of the XIENCE V(TM) USA post-approval study, with six hospital centers already recruitin...

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S. Food a...

The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Future Generation Treatment from Abbott Shows No Thrombosis, Low MACE Rates Out to One Year in Preliminary Clinical Study of Thirty Patients ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabs...

InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le

...hanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For fu...

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients

...up compared with patients receiving the Taxus drug eluting stent, but there were no stent thrombosis events a...gies to address the shortcomings with current drug eluting stents (DES), namely the safety concerns associate...gress with the next generation of pro-healing drug eluting stent (SES) featuring a combination of endothelial...

XTENT to Retain Investment Bank to Pursue Strategic Alternatives

...uch transaction. About XTENT XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause...

Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons

... Stent Forms Alliance to Jointly Develop Drug eluting Balloon Products RALEIGH, N.C., Jan. 12 /PRNe...ies also entered into an agreement to develop Drug eluting Balloon (DEB) products for cardiovascular applicat...es Cardiac Stents of various types, including Drug eluting Coronary stents used in critical cardiac care. In...

Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President

...g Worldwide Vice President of Sales and Marketing at Cordis Corporation where he oversaw the cardiovascular business including the market leading drug eluting stent, CYPHER (TM). Mr. Pinon received a bachelor's degree in biology from the University of Oregon . Terumo Heart, Inc. is a U.S. subsidiar...

Eluting in Biological Products

Autotrace SPE Workstation from Caliper Life Sciences

Description:... The unit can process up to six samples in parallel, automatically conditioning, washing, and eluting SPE cartridges with a choice of up to five reagents. The unit also segregates aqueous and solvent waste using separate waste lines for efficient, cost...
Company:Caliper Life Sciences

AccuSpot from Shimadzu Biotech

Description:...be performed with a higher degree of precision and with greater sequence coverage. AccuSpot technology Designed for on-line collection of fractions eluting from Capillary/Nano LC. Supports micro-fractionaction on MALDI-TOF/MS targets, for 96 or 384 well plates. Multiple plates can be spotted continuou...
Company:Shimadzu Biotech

Eluting in Biological Definition

Chromatography

...reverse" phase (RP-HPLC) stationary phases are hydrophobic. On an RP-HPLC column, then, hydrophobic analytes would tend to be retained on the column, eluting more readily as the proportion of the hydrophobic component of the mobile phase is increased. RP-HPLC has lower resolution than GC. Gel permeati...